In the NEOPRISM-CRC clinical trial led by UCL and UCLH, 32 patients with stage two or three bowel cancer received up to nine weeks of pembrolizumab before surgery instead of standard post-operative chemotherapy. After 33 months of follow-up, none of the patients experienced a cancer recurrence, wher